Lincoln Pharmaceuticals Ltd reports Net Profit of Rs. 10.92 crore, up19.47% in Q3FY2019-20


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Lincoln Pharmaceuticals Ltd
Company is building a strong portfolio in lifestyle and chronic segment especially in women healthcare and dermatology to complement its strong presence in acute segment

Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies reported excellent financial performance in the third quarter ended in December 2019. On the back of strong domestic and international business, the company posted 19.74% sales growth, 27.52% rise in exports and 19.47% rise in the EPS the quarter ended Q3FY19-20.

The company reported Net profit of Rs. 10.92 crore for the Q3 FY 2019-20 as against net profit of Rs. 9.14 crore in the corresponding period last year, growth of 19.47%. Net revenue for the quarter ended December 2019 reported at Rs. 101.56 crore was higher by 19.74% over previous fiscal’s same period net revenue of Rs. 84.81 crore. EPS for the Q3FY20 was reported at Rs. 5.46 per share for the as against EPS Rs. 4.57 in correspondence period Last year.

Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, "Despite a challenging business environment, company is delivering robust financial performance quarter over quarter maintaining healthy growth in revenue, profitability and expects to continue the growth momentum in the coming years. Exports sales for Q3FY20 stood at Rs. 86.21 crore, growth of 27.52% Y-o-Y. Our growth has been attributed to a strong performance in the domestic and international markets, new product approvals, better margin products, healthy customer and product base coupled with cost-effective strategies to improve operational efficiency. With best in class R&D capabilities supported by strong industry experience and improving market dynamics, we are confident of achieving improved performance and maximize shareholders’ wealth in the near to medium term.”

Company is building a strong portfolio in lifestyle and chronic segment especially in women healthcare and dermatology to complement its strong presence in acute segment. Company has recently secured patent for its liquid Diclofenac Metered-Dose Rectal Spray (Diclofenac Rectal Spray) and is planning to launch very soon. The Company is also planning to apply for a Global Patent for this novel solution.

During the quarter, board of directors of the company approved the scheme of amalgamation between Lincoln Parenteral Ltd ("Transferor Company") and Lincoln Pharmaceuticals Limited ("Transferee Company"). Lincoln Parenteral Ltd is subsidiary company of Lincoln Pharmaceuticals Limited engaged in the business of small Parenteral Injection Products. The corporate restructuring aims to bring lot of synergies for both companies including competitive strength, operational efficiencies, productivity gains, and logistic advantages, thereby significantly contributing to future growth.

Performance for Nine Months ended December 2019

As a result of expansion in geographical reach in domestic markets, relentless focus on exports and sustained marketing, the Net sales for the nine months ended December 2019 was reported at Rs. 314.88 crore, higher by 7.33% over previous fiscal’s same period net sales of Rs. 293.38 crore. The company reported Net profit of Rs. 42.53 crore for the nine months ended December 2019 as against net profit of Rs. 40.22 crore in the corresponding period last year, growth of 5.74%. EPS for the 9MFY20 was reported at Rs. 21.25 per share. Exports for the 9MFY20 stood at Rs. 174.74 crore, up 14.60%as against exports of Rs. 152.48 crore in 9MFY19.

Tags : #Lincolnpharmaceuticals #Q3result #Netprofitup

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026